Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire
In June 2025, Eli Lilly reported Phase III ACHIEVE-1 Survodutide (BI 456906): Boehringer Ingelhium Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium
Having hypothyroidism does not make these medications less effective or more dangerous when thyroid hormone levels are appropriately managed with levothyroxine
Many find 4mg or 8mg effective Consider microdosing if GI side effects are limiting your progress Use a calculator to visualize your protocol and track steady state References Jastreboff AM, Kaplan LM, Fras JP, et al
Healthy Fats : Avocados, nuts (almonds, pistachios, peanuts), seeds, olive oil
In addition, Axxam offers a fully cloned panel of taste receptors with ready-to-use assays and provides the flexibility to rapidly develop custom cell-based assays tailored to specific project needs